RSV F Protein Inhibitors are used for the prevention and treatment of respiratory syncytial virus (RSV) infections. They work by binding to the fusion protein, which blocks the virus's entry into host cells, preventing infection and reducing the severity of the disease.
NIRSEVIMAB reduces the risk of infections caused by respiratory syncytial virus (RSV). It does not treat RSV. It is still possible to get RSV after receiving this medication, but the symptoms may be less severe or not last as long. It works by helping your immune system slow or stop the spread of the virus in the body. It is a monoclonal antibody.
PALIVIZUMAB prevents severe infections caused by the respiratory syncytial virus (RSV). It does not treat RSV. It is still possible to get RSV after receiving this medication, but the symptoms may be less severe or not last as long. It works by helping your immune system slow or stop the spread of the virus in the body. It is a monoclonal antibody.
Disclaimer: Popularity is based on total prescriptions for the brand and generic versions of each drug, regardless of the condition being treated. Some drugs are prescribed for multiple conditions.
Subscribe and save
Get prescription saving tips and more from GoodRx Health. Enter your email to sign up